Conclusions
bleeding, gastrointestinal injury, GIB
SECONDARY, ISCHEMIC HEART DISEASE, BLEEDING
In this secondary analysis of the OPT-PEACE randomized clinical trial, serial MCEs showed that among patients without high bleeding risk who received a 6-month DAPT course after PCI, aspirin, clopidogrel, and their combination all were associated with gastrointestinal injury progression. Such progression is known to predispose patients to subsequent overt GIB. Use of aspirin alone had the lowest incidence of gastrointestinal injury progression between 6 and 12 months. Conversely, patients receiving clopidogrel monotherapy or DAPT were more likely to experience progressive gastrointestinal injury. Further studies are warranted to determine whether incorporating the findings from routine MCEs into clinical decision-making for the selection and duration of antiplatelet therapy may improve outcomes for patients with ischemic heart disease.